Quince Therapeutics, Inc.QNCXNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank38
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$-38.98M
↓ 16% vs avg
Percentile
P38
Within normal range
Streak
2 yr
Consecutive declineContracting
Average
$-33.65M
Historical baseline
PeriodValueYoY Change
TTM$-38.98M-21.2%
2024$-32.16M-74.3%
2023$-18.45M+58.2%
2022$-44.17M+30.0%
2021$-63.11M-24.1%
2020$-50.87M-52.6%
2019$-33.33M-179.9%
2018$-11.91M-20.2%
2017$-9.90M-